Three Biotech Companies Redefining Value Creation Through Dual Strategies

A New Model for the Modern Issuer

BRISTOL, TN / ACCESS Newswire / October 7, 2025 / Quantum BioPharma Ltd. (FRA:0K91) is quietly redrawing the boundaries of what a biotechnology company can be. The company has evolved beyond traditional R&D into a diversified enterprise-one that integrates clinical innovation, consumer health commercialization, and advanced market infrastructure.

In an era where science, data, and capital efficiency intersect, Quantum BioPharma represents a new category of public issuer: the digitally engineered life sciences company.

From Molecules to Markets

Quantum's foundation remains firmly rooted in neuroscience. Its flagship program, Lucid-MS (Lucid-21-302), is a proprietary neuroprotective compound targeting demyelination and neurodegeneration in multiple sclerosis (MS).

In collaboration with Massachusetts General Hospital, Quantum is conducting a pioneering imaging study using the PET tracer [^18F]3F4AP to monitor remyelination in vivo-a biomarker-driven approach that could redefine how neurorepair is measured and quantified.

This clinical focus demonstrates the company's disciplined scientific core. But Quantum's broader strategy reveals something more ambitious: an integrated approach to how research, data, and capital are aligned for long-term growth.

Reframing the Corporate DNA

Quantum has aligned its operations around three complementary verticals:

• Biopharmaceutical Development - advancing Lucid-MS and related neurological compounds through translational research.

• Consumer Health Commercialization - through Celly Nu, developer of the unbuzzd™ beverage, a clinically validated formulation that supports faster alcohol metabolism and cognitive recovery. Quantum retains pharmaceutical rights to the formulation and earns a royalty stream of 7 percent on sales until USD $250 million is paid, and 3 percent thereafter in perpetuity.

• Market Access Innovation - utilizing modern trading and settlement technology to expand shareholder reach and enhance transparency for international investors.

In January 2025, Quantum's shares were approved for dual listing on Upstream, a regulated digital exchange environment designed for near-instant settlement and wider global participation. The listing underscores Quantum's commitment to accessibility, speed, and modernization within the public-market ecosystem.

A Blueprint for the Modern Capital Era

Quantum's approach goes beyond therapeutic innovation-it reflects a holistic view of how public companies can adapt to a new financial architecture. The company's leadership views its next-generation listing strategy and capital design as extensions of the same precision that drives its research pipeline: structure, clarity, and data integrity.

By modernizing how its equity trades and how investors engage with the company, Quantum is creating what The Vanderbilt Report defines as a "digital balance-sheet framework"-a structure that supports transparency, efficiency, and long-term shareholder confidence.

A Convergence of Science and Strategic Capital

Quantum BioPharma stands at the intersection of two powerful growth curves:

• The global biotechnology market, projected to exceed $3 trillion by 2030, driven by advances in neurodegenerative and regenerative medicine.

• The rise of next-generation market infrastructure, which is transforming how global issuers connect with investors and measure performance in real time.

By aligning these forces, Quantum BioPharma is building what The Vanderbilt Report identifies as a next-generation issuer model-one where scientific credibility, operational transparency, and shareholder connectivity define enterprise value.

The Institutional View

For investors and analysts, Quantum BioPharma represents more than a biotech story. It's a forward signal of how public companies will evolve as science, technology, and capital markets continue to merge.

From its neurorepair pipeline to its commitment to transparent, technology-enabled investor access, the company is crafting a framework that others may soon follow-a model of resilience, data-driven governance, and investor alignment in an era defined by rapid information flow.

In a market increasingly shaped by precision, speed, and trust, Quantum BioPharma is positioning itself not just as a participant-but as a prototype.

See the full report at The Vanderbilt Report

About The Vanderbilt Report

The Vanderbilt Report was founded with a clear mission - to redefine how a new generation engages with Wall Street. We deliver trusted market intelligence, founder insights, and institutional-grade analysis designed for today's dynamic investment landscape. By blending traditional reporting with real-time data and narrative-driven coverage, The Vanderbilt Report provides clarity and credibility for investors, funds, and public companies navigating the modern markets.

Compliance Note:

This announcement is based on Quantum BioPharma Ltd.'s public filings and official disclosures, including its clinical updates, market announcements, and investor communications. It does not constitute investment advice, a solicitation, or a recommendation to buy or sell securities.

CONTACT

Vanderbilt Report Media Relations

Kristen Owens

info@vanderbiltreport.com

SOURCE: Quantum BioPharma Ltd

View the original press release on ACCESS Newswire

EXECUTIVE CHAIRMAN & CEO OF MEDICUS TO PARTICIPATE IN A PANEL DISCUSSION

The Summit theme "unlocking the $1 Trillion Wealth transfer in Dubai"

PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / October 7, 2025 / Medicus Pharma Ltd. ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce that it will present at the Family Office Summit in Dubai with the theme of "Unlocking the $1 Trillion Wealth Transfer in Dubai".

Panel Discussion Event Details

Date: October 9, 2025

Time: 11:20-11:50 a.m. local time

Location: Park Hyatt, Dubai

The summit will bring together thought leaders, opinion makers, executives and entrepreneurs from around the world to deliberate on unlocking the wealth transfer in Dubai.

Dr. Raza Bokhari, Medicus's Executive Chairman & CEO, in his presentation, will focus on innovation in biotech/life sciences sector, the role of Artificial intelligence (AI) in drug development as well as the United Arab Emirates (UAE) Genomic project as an untapped differentiator.

Additional information on the Family Office Summit is available on the event website at https://familyofficesummit.ae/dubai/.

Medicus is currently conducting a Phase 2 clinical study for SKNJCT-003 in nine (9) clinical sites across the United States which commenced randomizing patients in August 2024. SKNJCT-003 is a double blinded, placebo controlled triple arm proof of concept Phase 2 clinical study, designed to non-invasively treat basal cell carcinoma (BCC) of the skin using novel, patent protected, dissolvable Doxorubicin-containing microneedle arrays (D-MNA). In March 2025, the Company announced a positively trending interim analysis for SKNJCT-003 demonstrating more than 60% clinical clearance. The interim analysis was conducted after more than 50% of the then-targeted 60 patients in the study were randomized. The findings of the interim analysis are preliminary and may or may not correlate with the findings of the study once completed.In April 2025, the investigational review board approved to increase the number of participants in SKNJCT-003 to ninety (90) subjects. The Company is expanding its trial sites in Europe and has randomized more than 75% of the ninety (90) participants expected to be randomized in the study. In September 2025, the company received positive feedback from the Food and Drug Administration (FDA) regarding its Type C meeting supporting the development of Skinject, indicating that the company may follow 505(b)(2) regulatory pathway to non-invasively treat BCC using dissolvable D-MNA.

The Company also has a clinical study (SKNJCT-004) currently underway in the United Arab Emirates (UAE). The study is expected to randomize thirty-six (36) patients in six (6) sites in the UAE. Cleveland Clinic Abu Dhabi (CCAD) is the principal investigator, along with Sheikh Shakbout Medical City (SSMC), Burjeel Medical City (BMC), Rashid Hospital (RH), Clemenceau Medical Center (CMC) and American Hospital of Dubai (AHD). Insights Research Organization and Solutions (IROS), a UAE-based contract research organization, is coordinating the clinical study for the Company. IROS is a M42 portfolio company.

In August 2025, the Company completed the acquisition of Antev, a UK-based late clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse (AURr) episodes due to enlarged prostate.

Antev's flagship drug candidate is Teverelix trifluoroacetate (Teverelix TFA), a long-acting gonadotrophin-releasing hormone (GnRH) antagonist. Unlike GnRH agonists, which can cause an initial surge in testosterone levels, Teverelix directly suppresses sex hormone production without this surge, potentially reducing cardiovascular risks. This mechanism is particularly beneficial for patients with existing cardiovascular conditions. Teverelix is formulated as a microcrystalline suspension, allowing for sustained release and a six-week dosing interval, which may improve patient compliance and outcomes.

For further information contact:

Carolyn Bonner, President and Acting Chief Financial Officer

(610) 636-0184

cbonner@medicuspharma.com

Anna Baran-Djokovic, SVP Investor Relations

(305) 615-9162

adjokovic@medicspharma.com

About Medicus Pharma Ltd.

Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and potentially disruptive therapeutics assets. The Company is actively engaged in multiple countries, spread over three continents.

SkinJect Inc. a wholly owned subsidiary of Medicus Pharma Ltd., is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver a chemotherapeutic agent to eradicate tumors cells. The Company completed a phase 1 safety & tolerability study (SKNJCT-001) in March of 2021, which met its primary objective of safety and tolerability; the study also describes the efficacy of the investigational product D-MNA, with six (6) participants experiencing complete response on histological examination of the resected lesion. The Company is currently conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in the United States and Europe. The Company has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in the United Arab Emirates.

In August 2025, the Company announced its entry into a non-binding memorandum of understanding (the "MoU") with Helix Nanotechnologies, Inc. ("HelixNano"), a Boston Based biotech company focused on developing a proprietary advanced mRNA platform, in respect of their shared mutual interest in the development or commercial arrangement contemplated by the MoU. The MoU is non-binding and shall not be construed to obligate either party to proceed with a joint venture or any further development or commercial arrangement, unless and until definitive agreements are executed.

In August 2025, the Company completed the acquisition of Antev, a UK-based late clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse (AURr) episodes due to enlarged prostate.

Antev's flagship drug candidate is Teverelix trifluoroacetate (Teverelix TFA), a long-acting gonadotrophin-releasing hormone (GnRH) antagonist. Unlike GnRH agonists, which can cause an initial surge in testosterone levels, Teverelix directly suppresses sex hormone production without this surge, potentially reducing cardiovascular risks. This mechanism is particularly beneficial for patients with existing cardiovascular conditions. Teverelix is formulated as a microcrystalline suspension, allowing for sustained release and a six-week dosing interval, which may improve patient compliance and outcomes.

In September 2020, Antev completed a Phase 1 clinical trial in which Teverelix was shown to be well tolerated with no dose-limiting toxicities and demonstrated rapid testosterone suppression. The study included 48 healthy male volunteers. In February 2023, Antev also completed a Phase 2a study in fifty (50) patients with advanced prostate cancer (APC), where Teverelix achieved the primary endpoint of greater than 90% probability of castration levels of testosterone suppression (97.5%) but the secondary endpoint of maintaining this rate above 90% was not met with the probability dropping to 82.5% by Day 42.

In January 2023, the FDA, reviewed the Phase 1 and Phase 2a data and provided written guidance on Antev's proposed Phase 3 trial design for Teverelix. This milestone supports the Company's clinical plans to develop Teverelix as a treatment for advanced prostate cancer patients with increased cardiovascular risk.

In December 2023, FDA approved the Phase 2b study design in advanced prostate cancer covering 40 patients.

In November 2024, FDA approved the Phase 2b study design in acute urinary retention covering 390 patients.

Cautionary Notice on Forward-Looking Statements

Certain information in this news release constitutes "forward-looking information" under applicable securities laws. "Forward-looking information" is defined as disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes, without limitation, the development of Teverelix and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of Teverelix for AURr and high CV risk prostate cancer, and the potential market opportunities related thereto, the MOU, including the potential signing of definitive agreements between Medicus and HelixNano and the development of thermostable infectious diseases vaccines by combining HelixNano's proprietary mRNA vaccine platform with Medicus's proprietary microneedle array (MNA) delivery platform, the Company's aim to fast-track the clinical development program and convert the SKNJCT-003 exploratory clinical trial into a pivotal clinical trial, and approval from the FDA and the timing thereof, plans and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of SkinJect through SKNJCT-003 and SKNJCT-004, and the potential market opportunities related thereto, the commencement of the SKNJCT-004 study and the potential results of and benefits of such study. Forward-looking statements are often but not always, identified by the use of such terms as "may", "on track", "aim", "might", "will", "will likely result", "could," "designed," "would", "should", "estimate", "plan", "project", "forecast", "intend", "expect", "anticipate", "believe", "seek", "continue", "target", "potential" or the negative and/or inverse of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including those risk factors described in the Company's annual report on form 10-K for the year ended December 31, 2024 (the "Annual Report"), and in the Company's other public filings on EDGAR and SEDAR+, which may impact, among other things, the trading price and liquidity of the Company's common shares. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

SOURCE: Medicus Pharma Ltd

View the original press release on ACCESS Newswire

BRISTOL, TN / ACCESS Newswire / October 1, 2025 / Coeptis Therapeutics Holdings, Inc. today announced that The Vanderbilt Report has published coverage of the company following its recent SEC filings.

According to disclosures filed on January 31, 2025, Coeptis' technology division was assigned a $660.3 million fair market value. In addition, management has outlined a planned biotech spin-out, valued at approximately $75 million, together with tax advantages that may support future profitability.

The Vanderbilt Report reviewed these filings and highlighted a combined valuation framework of approximately $835 million, marking a milestone in Coeptis' transition from a pure biopharmaceutical operator to a dual-sector enterprise spanning both life sciences and advanced technology.

Why This Matters:

• Credible Benchmark: The $660M valuation stems directly from Coeptis' SEC disclosures.

• Biotech Spin-Out: Management intends to distribute oncology and cell therapy programs on a 1:1 basis to shareholders, with a proposed uplisting to Nasdaq.

• Independent Coverage: Vanderbilt Report has published analysis of these disclosures, underscoring the significance of the dual-sector model..

Read the full Vanderbilt Report analysis here

About Coeptis Therapeutics Holdings, Inc.

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc., SNAP Biosciences, Inc., and Coeptis Technologies (collectively "Coeptis"), is a biopharmaceutical and technology company.

The biopharmaceutical divisions focus on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases. Coeptis' therapeutic portfolio includes assets licensed from Deverra Therapeutics, such as an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. Coeptis is also developing SNAP-CAR, a universal, multi-antigen CAR technology licensed from the University of Pittsburgh, alongside its GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and researchers at the Karolinska Institute.

Building on its core competencies, Coeptis has recently established a Technology Division, which includes AI-powered marketing software and robotic process automation tools acquired from NexGenAI Solutions Group. These technologies are designed to optimize operations and enhance overall efficiency.

Headquartered in Wexford, PA, Coeptis is committed to advancing patient outcomes through innovation while operating under the highest standards of compliance and regulatory oversight. For more information, visit https://coeptistx.com.

Compliance Note: This announcement is based on Coeptis Therapeutics' SEC filings (10-Q, S-4, valuation disclosures) and public information. It does not constitute investment advice, a solicitation, or a recommendation to buy or sell securities.

CONTACT

Vanderbilt Report Media Relations

Kristen Owens

info@vanderbiltreport.com

SOURCE: Coeptis Therapeutics

View the original press release on ACCESS Newswire